- CEO
- Zhao Li Xiao
- Full Time Employees
- 542
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- A101, Building 2 Shenzhen GD China 518126
- IPO Date
- Feb 9, 2021
- Business
- Shenzhen Bioeasy Biotechnology Co., Ltd. (300942.SZ) develops, manufactures, and sells rapid testing instruments, reagents, and related services primarily for food safety, animal health diagnostics, clinical applications, and public safety detection. The company offers an extensive range of products including colloidal gold immunochromatographic test strips and ELISA kits for detecting antibiotics, mycotoxins such as aflatoxin and zearalenone, pesticides, and adulterants in dairy products like milk; cereals and feed; fruits and vegetables; meat and seafood; honey and eggs; veterinary diagnostics for ruminants, swine, avian, and companion animals such as brucella antibody, African swine fever virus, and pregnancy rapid tests; clinical POCT solutions for infectious diseases including coronavirus, tropical infections, gastrointestinal pathogens, and drug abuse screening; as well as fluorescence PCR kits, nucleic acid extraction kits, portable analyzers, pretreatment columns, and certified reference materials. Founded in 2007 and headquartered at No. 101, Liuxian Yirui Biological Building in Shenzhen's Bao'an District, China, the company operates globally across more than 60 countries with approximately 480 employees, serving food production, processing, agriculture, breeding, laboratories, and healthcare sectors. Its wholly-owned subsidiary Shenzhen Anieasy Biotechnology Co., Ltd., established in January 2022, bolsters animal health diagnostics with advanced platforms in immunodiagnostics, molecular diagnostics, and mRNA vaccine technologies. Recent developments include Wang Tianyi's completion of a 6.59% stake acquisition in 2025, approval of a final cash dividend for fiscal year 2024 payable in May 2025, ongoing expansion of pet infectious disease detection products into hospitals, new product launches such as fluorescence quantitative rapid tests for aflatoxin M1 in milk (15-150 ppt) and multi-residue antibiotic kits like 4IN1 BSCT and Amino 3IN1 GSN, participation in international events like IAFP 2024, and sustained R&D with over 110 patents and 200 team members focusing on one-stop food safety ecosystems.